Clinical Trial Update: A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial of siltuximab or placebo with Velcade and dexamethasone in relapsed or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Sylvant (siltuximab)
• Velcade (bortezomib)

Snippet

Sponsor: Centocor, Inc. | Conditions: Multiple Myeloma | Phase 3 | Status: WITHDRAWN